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Summary
Melatonin is a widely publicized "magical drug ". Claims of its use include regulation of sleep, circadian
rhythm, mood, immune system and reproduction, anti-aging, protection against cancer, and treatment of AIDS. This
article reviews the evidence for its use in sleep disorders. Its possible indications and adverse effects are
discussed. (HK Pract 1997; 19:669-672)
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Introduction
Melatonin is secreted by the
pineal gland in the brain. It is also
present naturally in some foods. It has
been widely publicized to have health
benefits, including regulation of sleep,
circadian rhythm, mood, reproduction,
tumor growth, immune response, and
even aging. Articles on melatonin
appear in newspapers, books and
magazines. A recent cover story in
Newsweek boosted melatonin as a hot
sleeping pill which is both natural and
cheap'. In the US, sale of melatonin
is estimated at 200 to 350 million
dollars annually.2 Melatonin can be
bought without a prescription as a
dietary supplement in Hong Kong.
General practitioners may come across
patients who seek their opinions on
this widely publicized "magical drug".
The author reviews here the recent
scientific evidence on this topic and
discusses the use of melatonin in sleep
disorders.
Physiology, pharmacology
and adverse effects
Melatonin secretion increases
soon after the onset of darkness and its
level is highest at 2-4 a.m. Its
secretion is suppressed by a sufficient
intensity of light (e.g. 2500 lux for 2
hours). However, light of domestic
intensity e.g. 200-300 lux applied for
30 minutes could also partially
suppress melatonin secretion.3 Mela-
tonin level is highest in childhood; and
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from puberty, there is a secular
decline.4 Physiological consequences
of this decline in human remain
unclear.
The nocturnal peak in melatonin
secretion matches the trough of body
temperature and the peak in sleep
propensity in healthy individuals.5
Nevertheless, suppression of melatonin
secretion with adrenergic antagonists
has not been shown to have major
effects on sleep. In both nocturnal and
diurnal animals, melatonin secretion
occurs at night-time rather than at the
time of sleep.3 The evidence suggests
that melatonin synchronizes sleep-
wakefulness with the light-darkness
cycle. It plays a role in the timing of
sleep but does not directly induce
sleep.
Exogenous melatonin has a very
short half-life of half-an-hour. It is
excreted wi th in 2-4 hours after
ingestion.6 This is in contrast to the
normal melatonin profile which lasts
for 10-14 hours from early evening to
the next morning. When exogenous
melatonin is given to healthy adults, it
produces a time-dependent hypnotic
effect7 (latency to maximum hypnotic
effect varies from about 4 hours when
melatonin is given at noon to 1 hour
when melatonin is taken at 9 p.m.).
The hypnotic effect can be produced
by variable doses of melatonin (as low
as 0.3 mg).8 The bioavailability of
orally administrated melatonin varies
widely.6 The usual oral dose (1 to
5 mg) that can be bought over the
counter results in a 10 to 100 times
higher serum melatonin concentration
than that of the physiological night-
time peak. The mechanism underlying
its hypnotic effect is closely linked to
melatonin's hypothermic property.9
Besides the hypnotic effect,
melatonin also possesses a time-
keeping property. When given in the
early morning, melatonin can shift the
body clock later and when melatonin
is taken in the late afternoon or early
evening, it can shift the body clock
earlier.3 This time-keeping property
will be further elaborated under the
section on its use in circadian rhythm
sleep disorders.
When melatonin is used, subjects
s h o u l d pay a t t e n t i o n to the
preparation's purity and its adverse
effects. A few recent editorials
published in scientific journals have
voiced concerns about melatonin's
safety.2'10, 11 If the melatonin is derived
from animal pineal glands, it can
transmit viruses from the animal to
human. Contaminants in melatonin
during its manufacturing process may
give rise to sensi t ivi ty reaction.
Although studies on rodents have
found low toxicity of melatonin on
short term use,12 no large scale and
long term studies have been done in
human. Arendt studied 386 subjects
taking 5 mg of melatonin for 7 days to
alleviate jet lag symptoms.13 The side
effects reported by the subjects were
sleepiness (8.9%), headache (2.9%),
giddiness (2%), and nausea (0.9%). In
other studies, melatonin is reported to
disturb sleep pattern,14 worsen or
precipitate depression, inhibit fertility,
suppress sex drive, cause hypothermia
and retinal damage.2 Cerebral and
coronary vasoconstriction induced by
melatonin has also been reported in
animal studies.2 It is not yet clear how
common the adverse effects are.
Nevertheless, subjects on long term
melatonin should receive regular
monitoring.
Use of melatonin in sleep
disorders
Insomnia
Insomnia is a very common
complaint . Its prevalence in
communities varies from 13.4-48%15
The primary diagnoses amongst 216
insomnic patients according to the
International Classification of Sleep
Disorders (ICSD)16 are sleep disorder
associated wi th mood disorder
(32.3%), p s y c h o p h y s i o l o g i c a l
insomnia (12.5%), delayed sleep phase
syndrome (7%), inadequate sleep
hygiene (6.2%), and sleep disorder
associated with anxiety disorder
(5.4%) 17 Previous studies have
reported that patients with primary
insomnia (includes psychophysio-
logical insomnia, sleep state mis-
perception and idiopathic insomnia in
the ICSD) have a lower peak melatonin
concentration than age-matched
controls.18, 19 Melatonin has also been
used in patients with primary insomnia
and the results are mixed. A few
studies have found that melatonin can
improve sleep initiation, maintenance
and quality.20-21 On the other hand,
Ellis22 and James23 both reported that
melatonin was not superior to placebo
in improving sleep in patients with
primary insomnia.
In view of the diagnostic hetero-
geneity in patients with insomnia, the
tasks of the family physician are
careful evaluation and accurate
diagnosis of the complaint. At present,
treatment of primary insomnia with
melatonin should not be recommended
until there is further evidence of its
efficacy from clinical trials.
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Key messages
1. Melatonin is secreted by the pineal gland and its level peaks at 2-4 a.m.
2. Melatonin synchronizes sleep-wakefulness with the light-darkness cycle and possibly other circadian
rhythms. It does not directly induce sleep.
3. Preliminary evidence supports the use of melatonin in the treatment of jet lag and sleep phase
syndromes.
4. The efficacy of melatonin in primary insomnia patients and shift workers is not adequately documented
by clinical trials. Its routine use is not recommended.
5. Use of low dose (1-5 mg) of melatonin is recommended. Beware of the preparation's purity and its
adverse effects. Regular monitoring by a clinician is recommended.
Circadian rhythm sleep disorders Sleep phase syndromes
Jet lag
Jet lag is a common problem for
air travelers after a flight through
several time zones. Disturbed sleep,
loss of mental efficiency, and tiredness
during the day are commonly reported
in the first few days after the air travel.
The symptoms are considered to be
due to desynchronisation of circadian
rhythms, such as the sleep-wake cycle,
with local time and due to lack of
sleep. Melatonin has been used
successfully to reduce the symptoms of
jet jag in previous studies.24'25 For
westwards flight (e.g. Hong Kong to
London), 5 mg of melatonin can be
given postflight for 4 days at local
bedtime. When traveling eastwards,
the same dose of melatonin can be
taken preflight for 3 days at the late
afternoon and for 4 days postflight at
local bedtime.
In the ICSD, sleep phase
syndromes consist of advanced sleep
phase syndrome, delayed sleep phase
syndrome, irregular sleep-wake pattern
and non-24-hour sleep-wake disorder.
They are disorders in which the sleep
onset and wake times are respectively
advanced (e.g. desired bedtime from
7 p.m. - 2 a.m.); delayed (e.g. desired
bedt ime from 4 a.m. - noon) ;
disorganized; or chronically delayed
for 1 -2 hour daily, in relation to the
conventional social sleep and wake
times (e.g. midnight - 8 a.m.).
Insomnia, difficulty in awakening
spontaneously and excessive sleepi-
ness are common complaints because
of the mismatch between the desired
and the conventional social sleep and
wake times. Melatonin has been used
successfully in delayed sleep phase
syndrome26 and in blind subjects27 or
brain damaged children28 with irregular
sleep-wake pattern or non-24-hour
sleep wake disorder. Melatonin 5 mg
can be given at the socially desirable
bedtime (e.g. 10 p.m.) to stabilise the
sleep onset time. Relapses have been
reported when melatonin is stopped.
Shift work
There is very few published data
on the use of melatonin in shift work.
One preliminary report described shift
workers taking melatonin at the desired
bedtime (6-7 a.m.) during their 7 days
of night shift.29 The subjects reported
that melatonin use could improve sleep
and on-shift alertness. Nevertheless,
there is a concern by some researchers
that wrongly timed melatonin may
induce sleepiness at work.
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Conclusion
Studies on the clinical use of
melatonin are very limited. This can
be explained by a lack of financial
suppor t f rom pha rmaceu t i ca l
companies. Melatonin is present
naturally in foods and hence nobody
can claim the product license. When
compared to the revenue from
melatonin sales, the resources used in
melatonin research is meagre.
In conclusion, there is preliminary
evidence to support using melatonin in
the treatment of jet lag and circadian
rhythm sleep disorders. In patients
with primary insomnia and for shift
workers , me la ton in is not yet
recommended for clinical use until its
efficacy and safety issues are more
clearly defined. •
References
1. Cowley G. Melatonin. Newsweek 1995 Aug
14:466-469.
2. Lamberg L. Melatonin potentially useful but
safety, efficacy remain uncertain. JAMA 1996;
276:1011-1014.
3. Arendt J. Melatonin and the mammalian pineal
gland. London: Chapman & Hall, 1995.
4. Waldhauser F, Weiszenbacler G, Frisch H, et
al. Fall in nocturnal serum melatonin during
prepuberty and pubescence. Lancet 1984;1:
362-365.
5. Akerstedt T, Froberg JE, Friberg W, el al.
Melatonin excretion, body temperature and
subjective arousal dur ing 64 hours of sleep
deprivation. Psychoneuroendocrinology 1979;
4:219-225.
6. Waldhauser F, Waldhauser M, Lieberman HR,
et al. Bioavailabilty of oral melatonin in
humans. Neuroendocrinology 1984;39:307-
313.
7. Tzischinsky O, Lavie P. Melatonin possesses
time-dependent hypnotic effects. Sleep 1994;
17:638-645.
8. Zhdanova IV, Wurtman RJ, Morabito C, et al.
Effects of low oral doses of melatonin, given 2-
4 hours before habi tual bedtime, on sleep in
normal young humans. Sleep 1996; 19:423-431.
9. Hughes RJ, Badia P. Sleep-promoting and
hypothcrmic effects of dayt ime me la ton in
administration in humans. Sleep 1997;20:124-
131.
10. A r e n d t J . Melatonin. BMJ 1996:312:1242-
1243.
11. But ler RN. A wake-up ca l l for caut ion.
Geriatrics 1996:51:14-15.
12. Sugden D. Psychopharmacological effects of
melatonin in mouse and rat. J Pharmacol Exp
Ther 1983:222:587-591.
13. Arendt J. Clinical perspectives for melatonin
and its agonists. Biol Psychiatry 1994;35:l-2.
14. M i d d l e t o n BA, S tone BM, A r e n d t J .
Mela ton in and f ragmented sleep patterns.
Lancet 1996:348:551-552.
15. Weyerer S, Di l l ing H. Prevalence and
treatment of insomnia in the community: results
from the Upper Bavarian Field Study. Sleep
1991:14:392-398.
16. Diagnostic Classification Steering Committee,
Thorpy M J , c h a i r m a n . I n t e r n a t i o n a l
classification of sleep disorders: diagnostic and
coding manual. Rochester, MN: American
Sleep Disorders Association, 1990.
17. Buysee DJ, Reynolds III CF, Kupfer DJ, et al.
Clinical diagnoses in 216 insomnia patients
using the International classification of sleep
disorders (ICSD), DSM-IV and ICD-10
categories: a report from the APA/NIMH DSM-
IV Field Trial. Sleep 1994:17:630-637.
18. Attrnburrow MEJ, Dowling BA, Sharpley AL,
et al. Case-control study of evening melatonin
concentration in primary insomnia. BMJ 1996;
312:1263-1264.
19. Hajak G, Rodenbeck A, Staedt J, et al.
Nocturnal plasma melatonin levels in patients
suffering from chronic primary insomnia. J
PinealRes 1995:19:116-122.
20. Haimov I, Lavie P, Laudon M, et al.
Melatonin replacement therapy of elderly
insomniacs. Sleep 1995;I8:598-603.
21. Garfinkel D, Laudon M, Nof D, et al.
Improvement of sleep quality in elderly people
by controlled-release melatonin. Lancet 1995;
346:541-544.
22. Ellis CM, Lemmens G, ParkesJD. Melatonin
and insomnia. Sleep Res 1996:5:61-65.
23. James SP, Sack DA, Rosenthal NE, et al.
Melatonin administrat ion in insomnia.
Neuropsychopharmacology 1990;3:19-23.
24. Arendt J, Aldhous M, Marks V. Alleviation
of jet lag by melatonin: preliminary results of
controlled double blind trial. BMJ 1986;292:
1170.
25. Petrie K, Conaglen JV, Thompson L, et al.
Effect of melatonin on jet lag after long haul
nights. BMJ 1989:298:705-707.
26. DahlitzM, Alvarez B, Vignau J, et al. Delayed
sleep phase syndrome response to melatonin.
Lancet 1991:337:1121-1124.
27. Folkard S. Arendt J, A l d h o u s M, et al.
Melatonin stabilises sleep onset time in a blind
man w i t h o u t e n t r a i n m e n t of cort isol or
temperature rhythms. Neurosci Lett 1990; 113:
193-198.
28. Jan JE, Espezel H, Appleton RE. The
treatment of sleep disorders with melatonin.
Dev Med Child Neurol 1994;36:97-107.
29. Folkard S, Arendt J, Clark M. Can melatonin
improve shift workers' tolerance of the night
shift? Some preliminary findings. Chronobio
Int 1993:10:315-320
672
